Cargando…
Olmesartan Attenuates Kidney Fibrosis in a Murine Model of Alport Syndrome by Suppressing Tubular Expression of TGFβ
Despite the wide use of angiotensin II receptor blockers in the treatment of Alport syndrome (AS), the mechanism as to how angiotensin II receptor blockers prevent interstitial fibrosis remains unclear. Here, we report that treatment of olmesartan effectively targets the feedback loop between the re...
Autores principales: | Suh, Sang Heon, Choi, Hong Sang, Kim, Chang Seong, Kim, In Jin, Ma, Seong Kwon, Scholey, James W., Kim, Soo Wan, Bae, Eun Hui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6695622/ https://www.ncbi.nlm.nih.gov/pubmed/31390839 http://dx.doi.org/10.3390/ijms20153843 |
Ejemplares similares
-
CG200745, a Novel HDAC Inhibitor, Attenuates Kidney Fibrosis in a Murine Model of Alport Syndrome
por: Suh, Sang Heon, et al.
Publicado: (2020) -
Angiotensin-[1–7] attenuates kidney injury in experimental Alport syndrome
por: Choi, Hong Sang, et al.
Publicado: (2020) -
Chronic kidney disease attenuates the impact of obesity on quality of life
por: Suh, Sang Heon, et al.
Publicado: (2020) -
Role of Akt1 in renal fibrosis and tubular dedifferentiation during the progression of acute kidney injury to chronic kidney disease
por: Kim, Il Young, et al.
Publicado: (2021) -
Deletion of Akt1 Promotes Kidney Fibrosis in a Murine Model of Unilateral Ureteral Obstruction
por: Kim, Il Young, et al.
Publicado: (2020)